Cormark Brokers Lift Earnings Estimates for Biosyent Inc. (RX)
Biosyent Inc. (CVE:RX) – Investment analysts at Cormark upped their FY2017 earnings per share (EPS) estimates for shares of Biosyent in a report issued on Thursday. Cormark analyst D. Novak now expects that the company will earn $0.35 per share for the year, up from their previous forecast of $0.32.
Biosyent (CVE:RX) last issued its quarterly earnings data on Thursday, May 25th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.08 by $0.02. The company had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million. Biosyent had a net margin of 23.59% and a return on equity of 21.00%.
Biosyent Company Profile
BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.
Receive News & Ratings for Biosyent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.